Dapsone clinical trials: what the acne and safety data show

Last updated 2026-07-27

What clinical trials actually support topical dapsone for acne?

Two phase 3 trials underpin the FDA approval of dapsone gel 5% (Aczone) for acne vulgaris, and they're the backbone of everything marketed about "dapsone for acne." Both were 12-week, randomized, double-blind, vehicle-controlled studies in patients age 12 and older with mild to moderate acne, and together they enrolled more than 3,000 people ^[1]. The headline numbers are modest, not dramatic. In the pooled analysis, roughly 48% of patients using dapsone gel 5% reached "treatment success" (defined as a 2-grade improvement on the Global Acne Assessment Score) versus about 43% on vehicle gel alone, a statistically significant but not huge difference ^[1][2]. Inflammatory lesion counts dropped by around 41-42% with dapsone versus roughly 35% with vehicle over the 12 weeks ^[2]. A separate long-term safety study followed patients for 12 months of daily use and found no new safety signals, no clinically meaningful methemoglobinemia, and no hematologic toxicity even in patients later found to have G6PD deficiency ^[3]. That last point matters a lot. We'll come back to it, because it's the single biggest reason topical and oral dapsone get confused. The 7.5% gel formulation (once-daily dosing, versus twice-daily for the original 5%) went through its own phase 3 program, again showing statistically significant but modest superiority over vehicle in both adolescents and adults with moderate acne ^[4]. No trial has shown dapsone gel outperforming, say, topical retinoids or benzoyl peroxide head-to-head; the comparisons that exist are almost all against vehicle (an inactive gel), not against other active acne treatments. If you're deciding on a dose or routine, the practical next step is reading Dapsone Rx dosage rather than the trial papers themselves, since the label dosing (once or twice daily, depending on strength) is what actually applies to a prescription.

How big is the effect, really? (Dapsone gel vs vehicle, by the numbers)

Trial data tends to get rounded up in marketing copy. Here's what the actual FDA-reviewed numbers looked like across the major studies. | Study population | Dapsone gel success rate | Vehicle success rate | Duration |

Has oral dapsone ever been tested in clinical trials for acne?

No, not in any meaningful, FDA-reviewed sense. Oral dapsone's approved indications are leprosy (Hansen's disease) and dermatitis herpetiformis, the itchy blistering skin condition linked to celiac disease ^[5]. It is not FDA-approved for acne, and there is no phase 3 trial program establishing its efficacy or safety for that use. Some older, small case series and off-label reports describe oral dapsone used for severe inflammatory acne or acne fulminans that didn't respond to standard therapy, but these are not controlled trials, and they don't change the drug's label or its risk profile. Prescribing oral dapsone for routine acne is off-label use of a systemic antibiotic that carries hematologic risks the topical gel does not, because oral dosing produces blood levels the topical form barely reaches, per FDA absorption data ^[3]. This is the single most important distinction on this whole topic: topical dapsone gel has real trial data for acne. Oral dapsone does not. If you see oral dapsone recommended casually for acne online, that's not supported by the evidence base that got the topical product approved.

What does the FDA label actually say about G6PD testing before oral dapsone?

Before anyone starts oral dapsone, checking glucose-6-phosphate dehydrogenase (G6PD) status is a real, label-driven requirement, not an optional precaution. The FDA-approved prescribing information states that dapsone "should be used with caution in patients with G6PD deficiency" because it can trigger dose-related hemolysis and hemolytic anemia, and that this reaction "is more severe in patients with G6PD deficiency" ^[5]. G6PD deficiency is an inherited enzyme condition, more common in people of African, Mediterranean, Middle Eastern, and Southeast Asian descent, and it affects an estimated 400 million people worldwide according to World Health Organization figures . In G6PD-deficient red blood cells, oxidant drugs like dapsone can't be neutralized properly, so the cells break down faster than the bone marrow can replace them. A simple blood test (a G6PD enzyme activity assay) before starting oral dapsone is standard practice, and many clinicians also order a baseline complete blood count to track hemoglobin over the following weeks. This isn't a formality: hemolysis from oral dapsone can be severe enough to require transfusion in deficient patients, and it's largely preventable with a five-minute lab draw beforehand ^[5].

What are the serious risks of oral dapsone that don't apply to the topical gel?

Oral dapsone carries a real risk profile that has nothing to do with the topical acne gel, and lumping them together is the exact mistake this whole topic exists to prevent. Hemolytic anemia and methemoglobinemia are the most common serious adverse effects, occurring to some degree in most patients on higher oral doses, with more severe reactions concentrated in G6PD-deficient individuals ^[5]. Methemoglobinemia happens because dapsone's metabolites oxidize hemoglobin into a form that can't carry oxygen properly; symptoms include cyanosis (bluish skin), fatigue, and shortness of breath. Dapsone hypersensitivity syndrome is rarer but frightening: it's a delayed reaction, usually appearing 2 to 6 weeks after starting the drug, involving fever, rash, and organ involvement (commonly liver), and it carries a mortality rate that published case reviews put in the range of roughly 9-12% when it occurs . Agranulocytosis, a dangerous drop in infection-fighting white blood cells, is another rare but serious risk flagged in the drug's label, usually emerging within the first few months of treatment ^[5]. None of this shows up in the topical gel's safety data. The 12-month topical safety study found no clinically meaningful methemoglobinemia and no hemolytic events tied to treatment, including in patients with G6PD deficiency, because so little drug is absorbed through the skin ^[3]. That's the entire reason topical dapsone doesn't require G6PD screening while oral dapsone does.

Do you need a G6PD test before using topical dapsone gel for acne?

No. The FDA label and the key trials for dapsone gel 5% and 7.5% do not require G6PD testing before use, because systemic absorption through the skin is low enough that hemolysis and methemoglobinemia haven't shown up as clinical problems, even in G6PD-deficient patients studied in the year-long safety trial ^[3]. That said, some dermatologists still ask about known G6PD deficiency out of general caution, especially in patients using large amounts of gel over broad areas or combining it with other oxidant-stress medications. It's a reasonable question to ask your prescriber, but it is not a blocking requirement the way it is for oral dapsone. If your dermatologist has prescribed the topical gel and you're wondering about application amount, frequency, or how it fits with other acne products, the Dapsone Rx dosage guide and the Dapsone Rx dosage calculator walk through that without wading back into oral-drug trial data that doesn't apply to your prescription.

How does dapsone gel compare to other acne treatments in trials?

Almost every dapsone gel trial compares it to vehicle (inactive gel), not to another active acne drug, so head-to-head comparative data is thin. What exists suggests dapsone gel is a reasonable second-line or add-on option, not a first-choice monotherapy. Benzoyl peroxide and topical retinoids (like adapalene or tretinoin) have decades more trial data and are recommended as first-line topical therapy in the American Academy of Dermatology's acne guidelines . Dapsone gel's own trials show a 12-week success rate around 49% versus 43% for vehicle, a smaller relative jump than what's typically reported for combination retinoid/benzoyl peroxide regimens in comparable trial designs ^[1][2]. Where dapsone gel earns its place is in patients who can't tolerate the dryness and irritation of retinoids or benzoyl peroxide, or who have more inflammatory (rather than comedonal) lesions. It's also sometimes used in combination with those first-line agents rather than as a replacement, since the mechanisms differ (dapsone's anti-inflammatory action versus retinoid's comedolytic effect).

What side effects showed up in the topical dapsone trials?

The most common side effects reported in the phase 3 topical trials were local skin reactions, not systemic ones. Dryness, redness, and peeling at the application site occurred in a meaningful minority of patients, generally described as mild to moderate in the trial data ^[1][2]. A notable, somewhat unusual finding: when dapsone gel is applied at the same time as benzoyl peroxide, some patients develop a temporary yellow-orange skin discoloration at the site, an interaction specifically noted in the product labeling. Dermatologists typically advise applying the two products at different times of day if you're using both ^[1]. Systemic side effects, the kind associated with oral dapsone (hemolysis, methemoglobinemia), essentially did not appear in the topical trials at clinically meaningful rates. That's the main safety argument for the gel over any oral off-label use ^[3].

What does the evidence say about dapsone for dermatitis, more than acne?

Oral dapsone's most solid trial-backed dermatologic indication is dermatitis herpetiformis, the blistering, intensely itchy rash linked to gluten sensitivity and celiac disease. This is a genuinely FDA-approved use, not off-label, and clinical experience going back decades supports it as first-line drug therapy alongside a gluten-free diet ^[5]. For other inflammatory skin conditions sometimes treated with oral dapsone off-label (certain forms of vasculitis, bullous pemphigoid, some neutrophilic dermatoses), the evidence is mostly case series and small open-label studies rather than large randomized trials. That doesn't mean it doesn't work for these conditions; it means the evidence bar is lower than what exists for leprosy or dermatitis herpetiformis, and prescribing decisions rely more on clinical experience than trial data. Topical dapsone gel, by contrast, has never been trial-tested for dermatitis herpetiformis or other systemic inflammatory skin diseases; its trial program is specific to acne vulgaris ^[1][2][4]. The two forms really do live in separate evidence worlds.

If oral dapsone is prescribed, what should a patient expect in terms of monitoring?

Anyone starting oral dapsone should expect a monitoring schedule built around the specific risks the trials and post-marketing data have flagged, not a one-time prescription and forget-it approach. Baseline G6PD testing comes first, before the first dose, per the drug's labeling and standard clinical practice ^[5]. After that, clinicians typically order complete blood counts weekly for the first month, then every 2 weeks for the next two months, then periodically after that, watching hemoglobin, reticulocyte count, and white blood cell count for early signs of hemolysis or agranulocytosis. Liver function tests are also common early in treatment because dapsone hypersensitivity syndrome frequently involves the liver ^[5]. None of this monitoring schedule applies to topical dapsone gel for acne, which is applied at home without routine lab work. If you're ever offered oral dapsone for a skin condition and no one mentions a G6PD test or a monitoring plan, that's worth asking about directly before you fill the prescription.

Where does Dapsone fit into getting a legitimate prescription?

If a dermatology consult concludes that topical dapsone gel is a reasonable option for your acne, Dapsone Rx's provider-reviewed process connects you with a licensed prescriber who can evaluate whether it fits your case, with prescriptions filled through its pharmacy partner. Dapsone Rx doesn't compound or manufacture the medication itself; it's a route to a legitimate, provider-reviewed prescription rather than a source of the drug. That's worth saying plainly because so much confusion online blurs topical and oral dapsone together, and a provider-reviewed process is exactly where that distinction gets sorted out correctly, including whether G6PD testing or any other screening applies to your specific situation.

What should someone do next if they're considering dapsone for acne?

Start with the distinction, not the prescription. Topical dapsone gel (Aczone 5% or 7.5%) is the FDA-approved, trial-tested option for acne, with a modest but real effect size shown in large phase 3 trials ^[1][2][4]. Oral dapsone is a different drug, for different conditions, with a risk profile that includes hemolysis, methemoglobinemia, and rare but serious hypersensitivity syndrome, and it requires G6PD testing before anyone starts it ^[5]. For anyone actually prescribed the topical form, practical next reads include Dapsone Rx dosage, the Dapsone Rx dosage calculator, and Dapsone Rx cycle length for how long a typical course runs before reassessing results with a prescriber.

Frequently asked questions

Is dapsone gel FDA-approved for acne?

Yes. Dapsone gel 5% (Aczone) was FDA-approved for acne vulgaris based on two 12-week phase 3 trials, and a 7.5% once-daily formulation was later approved after its own phase 3 program. Both are approved for patients age 12 and older ^[1][4].

Is oral dapsone FDA-approved for acne?

No. Oral dapsone is FDA-approved for leprosy and dermatitis herpetiformis, not acne. Any use for acne is off-label, without a phase 3 trial program supporting it, and carries systemic risks (hemolysis, methemoglobinemia) that the topical gel does not ^[5].

Do I need a G6PD test before using dapsone gel for acne?

Generally no. Topical dapsone gel's trials, including a 12-month safety study, found no clinically meaningful hemolysis or methemoglobinemia even in G6PD-deficient patients, because skin absorption is low. G6PD testing is not a labeled requirement for the topical gel, unlike oral dapsone ^[3][5].

Why does oral dapsone require G6PD testing?

Because dapsone is an oxidant drug, and G6PD-deficient red blood cells can't neutralize that oxidant stress properly, leading to faster red blood cell breakdown (hemolysis). The FDA label specifically warns dapsone should be used with caution in G6PD deficiency due to more severe hemolytic reactions ^[5][6].

How effective is dapsone gel compared to a placebo gel in trials?

In pooled phase 3 trials, about 48.9% of patients on dapsone gel 5% reached treatment success at 12 weeks versus about 43.2% on vehicle gel, a statistically significant but modest difference. Inflammatory lesion reduction was roughly 41-42% versus 35% for vehicle ^[1][2].

What is dapsone hypersensitivity syndrome?

It's a rare, delayed reaction to oral dapsone, typically appearing 2 to 6 weeks after starting treatment, involving fever, rash, and organ damage (often the liver). Published reviews estimate mortality around 9-12% when it occurs, making it one of the more serious risks of oral dapsone ^[7].

Can topical dapsone cause methemoglobinemia like the oral form does?

Clinically meaningful methemoglobinemia has not shown up in topical dapsone trials, including a 12-month safety study, because so little drug is absorbed through the skin. Methemoglobinemia is a documented risk of oral dapsone, tied to its systemic blood levels, not the topical gel ^[3][5].

Is dapsone gel better than benzoyl peroxide or retinoids for acne?

There's no strong trial evidence it's better; most dapsone gel trials compare it only to vehicle, not to benzoyl peroxide or retinoids. Dermatology guidelines still list retinoids and benzoyl peroxide as first-line topical acne treatments, with dapsone often used as an add-on or alternative for irritation-prone patients ^[1][8].

What happens if you use benzoyl peroxide and dapsone gel together?

They can cause a temporary yellow-orange skin discoloration at the application site, a known interaction noted in dapsone gel's labeling. Most dermatologists recommend applying the two products at separate times of day (one in the morning, one at night) to avoid this ^[1].

Who is more likely to have G6PD deficiency?

G6PD deficiency is more common in people of African, Mediterranean, Middle Eastern, and Southeast Asian descent, and affects an estimated 400 million people worldwide, according to World Health Organization data. It's an inherited, X-linked enzyme condition, more frequently affecting males ^[6].

What monitoring is needed while on oral dapsone?

Baseline G6PD testing before starting, then regular complete blood counts (often weekly for the first month, then less frequently), watching for hemolysis, anemia, and agranulocytosis. Liver function is also monitored early on because dapsone hypersensitivity syndrome often involves the liver ^[5][7].

Are there clinical trials of oral dapsone specifically for acne?

No large, FDA-reviewed phase 3 trials of oral dapsone for acne exist. Some small case series describe off-label use in severe, treatment-resistant inflammatory acne, but this isn't controlled trial evidence and doesn't change the drug's approved indications or risk profile ^[5].

Sources

1. Draelos ZD et al., Journal of Drugs in Dermatology, dapsone gel phase 3 pooled analysis: Pooled 12-week treatment success and inflammatory lesion reduction rates for dapsone gel 5% versus vehicle
2. Lucky AW et al., 12-month safety study of dapsone gel including G6PD-deficient patients: 12-month topical safety data showing no clinically meaningful methemoglobinemia or hemolysis, including in G6PD-deficient patients
3. FDA, Aczone (dapsone) gel 7.5% prescribing information: Phase 3 approval data and once-daily dosing for dapsone gel 7.5%
4. Lorenz M et al., Dapsone hypersensitivity syndrome review, mortality estimate: Dapsone hypersensitivity syndrome timing (2-6 weeks) and mortality rate estimate
5. American Academy of Dermatology, Guidelines of care for acne vulgaris management: First-line status of topical retinoids and benzoyl peroxide in acne treatment guidelines